1
白云山
广州白云山医药集团股份有限公司是一家领先的中国跨国医药与健康产品集团，总部位于广东省广州市。2025年，集团年营收总额达776.6亿元人民币（约合108亿美元），位居全球中医药及大健康产业首位。集团业务覆盖医药全价值链，涵盖原料种植、现代提取、消费健康产品及国际贸易，旗下拥有白云山、陈李济（创立于明代）等旗舰品牌。
优势：（1）规模无与伦比，年营收达776.6亿元人民币，为全球中医药…
十大中药制造商及供应商排行
全球中药与健康产品制造业在2025-2026年正经历根本性的结构转型，更广泛的草药与传统医药市场规模约为3330亿美元，预计将以5.3%的复合年增长率扩张，到2032年达到4780亿美元。若以扩大的中药生态系统（涵盖生物制药延伸、家庭医疗设备及跨界消费健康产品）来衡量，该行业预计在2026年创造9267亿美元的产值，到2031年将攀升至1.31万亿美元，复合年增长率为7.18%。这一爆发式增长由全球人口老龄化、整合医学在西方医疗体系中的主流化，以及通过系统生物学和网络药理学方法对中药活性成分的科学验证日益增多所推动。目前，约55%的新中药应用源自慢性病管理的补充或替代疗法，而中药-化学药联合疗法现占全球新开发治疗产品的50%。
2025年的制…
前十榜单
2026.07 版本2
华润三九
华润三九医药股份有限公司（CR Sanjiu）是一家国有控股的OTC医药巨头，在中国感冒、咳嗽及消化道中成药领域占据无可争议的领先地位。该公司在深圳证券交易所上市（股票代码：000999.SZ），总部位于深圳，2025年实现年营收276.1亿元人民币，净利润同比增长18.05%至33.67亿元人民币，毛利率达行业领先的53.91%。集团运营着标志性的999（三九）品牌，并于2025年被中国工信部认定为卓越级智能工厂，旗下15家制造子公司均已通过ISO 14001…
3
云南白药
云南白药集团股份有限公司是中国最具标志性的制药企业之一，以其1902年创制的旗舰产品云南白药止血散而闻名。集团总部位于云南省昆明市，2025年实现年营收411.9亿元人民币，净利润达51.5亿元人民币（同比增长8.51%）。集团已从传统止血应用领域成功拓展至跨品类消费品领域，涵盖口腔护理（云南白药牙膏）、个人护理及功能性健康饮品，仅核心气雾剂产品线就创造了超过25亿元人民币的营收。
优势：（1
4
津村株式会社
Tsumura & Co. 是全球技术最先进、质量合规性最高的汉方（日本传统医学）药品制造商，在东京证券交易所上市（股票代码：4540.T）。公司总部位于东京，2025/2026财年实现净销售额1980亿日元（约合人民币95亿元），同比增长9.3%。在日本处方汉方制剂市场占据超过83%的压倒性份额，占日本医药市场总量的8.5%。其四家生产基地（分别位于静冈、茨城、上海和天津）以及位于北海道夕张的专属1000公顷药用植物农场，在全程条码级追溯体系下，每年生产超过2…
品牌
津村株式会社
成立时间
1893
员工规模
4272
覆盖范围
全球（日本、中国、东南亚）
生产基地
日本静冈与茨城；中国上海与天津；北海道夕张药用农场（1000公顷）
总部
日本
市场
东京证券交易所:4540.T
5
北京同仁堂股份有限公司
北京同仁堂股份有限公司是中国历史最悠久、文化底蕴最深厚的医药品牌，始创于1669年清朝康熙年间。该集团在上海证券交易所（600085.SH）和香港交易所（3613.HK）上市，2025年实现营业收入172.6亿元人民币，受宏观经济形势严峻及原材料成本飙升影响，同比下降7.2%。尽管面临短期财务压力，同仁堂在全球仍保持着无与伦比的品牌声望，尤其在急症心血管治疗、镇静安神类药物以及安宫牛黄丸、同仁牛黄清心丸等高端滋补制剂领域。该集团通过香港上市平台及直营中医诊所构建…
品牌
北京同仁堂股份有限公司
成立时间
1669
员工规模
1.7万
覆盖范围
全球（30多个国家，亚洲、北美、欧洲）
生产基地
中国北京；香港（海外分销中心）
总部
中国
市场
上交所:600085.SH, 港交所:3613.HK
6
中国中药控股有限公司
中国中药控股有限公司（China TCM）是全球最大的中药配方颗粒及中药饮片生产商，作为国药集团旗下的核心平台运营。公司于香港联交所上市（股票代码：0570.HK），总部位于广东佛山，2025年实现营业收入147.4亿元人民币，同比下降10.7%，主要因中药配方颗粒被纳入国家集中带量采购（VBP）所致。尽管面临财务压力，中国中药仍拥有全球最广泛的原料采购网络：在全国22个省份布局162个规范化生产基地，覆盖中药材种植面积超过30,600公顷，截至2025年，其1…
7
韩国人参公社
韩国人参公社（KT&G）是全球领先的红参及高端滋补保健品企业，总部位于韩国首尔与大田。作为KT&G（韩国烟草与人参）的全资子公司，该公司在韩国交易所上市（股票代码：033780.KS），2025年健康功能食品业务收入达1.137万亿韩元（约合人民币60亿元）。其旗舰品牌正官庄（JUNG KWAN JANG）在韩国国内红参市场占据约80%份额，业务已拓展至全球40多个国家。集团构建了从六年根人参种植、浓缩液提取到零售成品生产的全垂直整合供应链，旗下明星产品包括红参…
8
重庆太极实业（集团）股份有限公司
太极集团是中国领先的医药及中药健康产品制造商，总部位于中国重庆，成立于1993年（其前身涪陵中药厂始建于1972年）。作为国药集团的核心子公司，太极集团2025年实现年营收1050亿元人民币，净利润同比激增352.38%。公司在西南地区运营数十家GMP工厂…
9
漳州片仔癀药业股份有限公司
片仔癀药业是一家高端中药制造商，总部位于中国福建漳州，成立于1956年，其秘方渊源可追溯至明代。公司年营收达901亿元人民币，其旗舰护肝产品凭借奢侈药品品牌定位拥有非凡定价权。片仔癀拥有国家保密配方资质，掌控着中国最具价值中药品牌之一的独特生产链。公司员工约3000人，并已获得阿根廷天然牛…
10
石家庄以岭药业股份有限公司
以岭药业是中国领先的中药及创新药制造商，由吴以岭院士创立于1992年，总部位于中国河北石家庄。公司2025年实现年营收783.1亿元人民币，净利润128.6亿元人民币，经营性现金流飙升190.75%。以岭药业在全球独树一帜，将其独有的“络病理论”转化为涵盖理论、临床、制造与教育的全整合产业…
品牌
以岭药业
成立时间
1992
员工规模
1.5万
覆盖范围
中国 + 覆盖30多个国家（亚洲、非洲、美洲）
生产基地
中国石家庄与衡水智能制造基地，拥有国际CGMP认证胶囊与颗粒生产线，以及化学原料药合成平台（以岭万洲），拥有18个美国ANDA批准
总部
中国
市场
深交所：002603
常见问题
这些中药制造商是如何排名的？
我们的制造商排名基于生产数据和制造能力，而非品牌认知。 我们使用专有的生产能力综合评分（0-100分）对中药制造商进行评估，该评分在四个维度上加权：生产规模与产能（40%）、制造技术与质量体系（25%）、产品组合深度与多元化（20%）、以及全球影响力与财务韧性（15%）。
生产规模与产能（40%）是权重最高的维度，评估年原料药材处理量（吨）、成品制剂产出能力、GMP认证设施数量与物理占地面积、以及供应链垂直整合的深度——包括GAP标准药材种植基地的所有权。行业领导者如广州白云山每年通过数十家子公司工厂处理数十万吨原料药材，而云南白药运营着全球最大的三七预处理和提取中心。
制造技术与质量体系（25%）衡量自动化成熟度和质量基础设施。我们考察AGV引导物料搬运系统、连续逆流提取技术、工业物联网集成以及在线质量监测工具（如近红外光谱）的部署情况。津村茨城工厂代表了全球基准——其AGV车队在无尘环境中自主运输175公斤提取容器，使单线年产量增加45吨，同时消除了交叉污染风险。
产品组合深度与多元化（20%）评估中药类别的覆盖广度以及向化学药品、医疗器械和消费者健康产品的成功跨类别扩展。以岭药业以其双平台战略体现了这一维度：在呼吸类中药领域占据主导地位，同时通过其以岭万洲子公司运营18个美国ANDA批准的仿制药产品。
全球影响力与财务韧性（15%）评估国际收入贡献、在受监管西方市场的存在、运营现金流产生能力，以及应对极端原料成本周期的能力。像韩国人参公社这样在140多个国家有业务的公司得分较高，而在应对牛黄价格暴跌后展现出强劲现金流恢复能力的公司也获得认可。
财务数据来源于2025财年向证券交易所（上交所、深交所、港交所、东交所、韩交所）提交的年度报告。产能数据通过公司文件、工厂审计报告和国家医药行业协会数据库进行验证。市场规模估计与Persistence Market Research、Mordor Intelligence和IQVIA行业报告进行交叉核对。
所有排名每年更新一次，在经审计的财务报表发布后进行。可能会因重大并购事件、显著产能扩张或监管状态的重大变化而进行临时更新。
生产规模与产能（40%）是权重最高的维度，评估年原料药材处理量（吨）、成品制剂产出能力、GMP认证设施数量与物理占地面积、以及供应链垂直整合的深度——包括GAP标准药材种植基地的所有权。行业领导者如广州白云山每年通过数十家子公司工厂处理数十万吨原料药材，而云南白药运营着全球最大的三七预处理和提取中心。
制造技术与质量体系（25%）衡量自动化成熟度和质量基础设施。我们考察AGV引导物料搬运系统、连续逆流提取技术、工业物联网集成以及在线质量监测工具（如近红外光谱）的部署情况。津村茨城工厂代表了全球基准——其AGV车队在无尘环境中自主运输175公斤提取容器，使单线年产量增加45吨，同时消除了交叉污染风险。
产品组合深度与多元化（20%）评估中药类别的覆盖广度以及向化学药品、医疗器械和消费者健康产品的成功跨类别扩展。以岭药业以其双平台战略体现了这一维度：在呼吸类中药领域占据主导地位，同时通过其以岭万洲子公司运营18个美国ANDA批准的仿制药产品。
全球影响力与财务韧性（15%）评估国际收入贡献、在受监管西方市场的存在、运营现金流产生能力，以及应对极端原料成本周期的能力。像韩国人参公社这样在140多个国家有业务的公司得分较高，而在应对牛黄价格暴跌后展现出强劲现金流恢复能力的公司也获得认可。
财务数据来源于2025财年向证券交易所（上交所、深交所、港交所、东交所、韩交所）提交的年度报告。产能数据通过公司文件、工厂审计报告和国家医药行业协会数据库进行验证。市场规模估计与Persistence Market Research、Mordor Intelligence和IQVIA行业报告进行交叉核对。
所有排名每年更新一次，在经审计的财务报表发布后进行。可能会因重大并购事件、显著产能扩张或监管状态的重大变化而进行临时更新。
How Are These TCM Manufacturers Ranked?
Our manufacturer rankings are built on production data and manufacturing capability, not brand perception. We evaluate Traditional Chinese Medicine manufacturers using a proprietary Production Capability Composite Score (0-100) weighted across four dimensions: Production Scale & Capacity (40%), Manufacturing Technology & Quality Systems (25%), Product Portfolio Depth & Diversification (20%), and Global Reach & Financial Resilience (15%).
Production Scale & Capacity (40%) is the heaviest-weighted dimension, assessing annual raw herb processing throughput in metric tons, finished formulation output capacity, GMP-certified facility count and physical footprint, and the depth of supply chain vertical integration — including ownership of GAP-standard herb cultivation bases. Industry leaders like Guangzhou Baiyunshan process hundreds of thousands of tons of raw herbs annually through dozens of subsidiary factories, while Yunnan Baiyao operates the world's largest Panax notoginseng pre-processing and extraction center.
Manufacturing Technology & Quality Systems (25%) measures automation maturity and quality infrastructure. We examine deployment of AGV-guided material handling systems, continuous countercurrent extraction technology, industrial IoT integration, and online quality monitoring tools such as near-infrared (NIR) spectroscopy. Tsumura's Ibaraki factory represents the global benchmark — its AGV fleet autonomously transports 175 kg extraction containers in dust-free environments, increasing single-line annual output by 45 tons while eliminating cross-contamination risk.
Product Portfolio Depth & Diversification (20%) evaluates the breadth of TCM categories covered and successful cross-category expansion into chemical pharmaceuticals, medical devices, and consumer health products. Yiling Pharmaceutical exemplifies this dimension with its dual-platform strategy: dominating respiratory TCM while operating 18 US ANDA-approved generic drug products through its Yiling Wanzhou subsidiary.
Global Reach & Financial Resilience (15%) assesses international revenue contribution, presence in regulated Western markets, operating cash flow generation, and demonstrated ability to navigate extreme raw material cost cycles. Companies like Korea Ginseng Corporation with operations across 140+ countries score highly, while firms demonstrating strong cash flow recovery after navigating bezoar price collapses also earn recognition.
Financial data is sourced from FY2025 annual reports filed with stock exchanges (SHA, SZSE, HKEX, TYO, KRX). Production capacity data is verified against corporate filings, factory audit reports, and national pharmaceutical industry association databases. Market size estimates are cross-referenced with Persistence Market Research, Mordor Intelligence, and IQVIA industry reports.
All rankings are updated annually following the publication of audited financial statements. Interim updates may occur in response to major M&A events, significant production capacity expansions, or material changes in regulatory status.
Production Scale & Capacity (40%) is the heaviest-weighted dimension, assessing annual raw herb processing throughput in metric tons, finished formulation output capacity, GMP-certified facility count and physical footprint, and the depth of supply chain vertical integration — including ownership of GAP-standard herb cultivation bases. Industry leaders like Guangzhou Baiyunshan process hundreds of thousands of tons of raw herbs annually through dozens of subsidiary factories, while Yunnan Baiyao operates the world's largest Panax notoginseng pre-processing and extraction center.
Manufacturing Technology & Quality Systems (25%) measures automation maturity and quality infrastructure. We examine deployment of AGV-guided material handling systems, continuous countercurrent extraction technology, industrial IoT integration, and online quality monitoring tools such as near-infrared (NIR) spectroscopy. Tsumura's Ibaraki factory represents the global benchmark — its AGV fleet autonomously transports 175 kg extraction containers in dust-free environments, increasing single-line annual output by 45 tons while eliminating cross-contamination risk.
Product Portfolio Depth & Diversification (20%) evaluates the breadth of TCM categories covered and successful cross-category expansion into chemical pharmaceuticals, medical devices, and consumer health products. Yiling Pharmaceutical exemplifies this dimension with its dual-platform strategy: dominating respiratory TCM while operating 18 US ANDA-approved generic drug products through its Yiling Wanzhou subsidiary.
Global Reach & Financial Resilience (15%) assesses international revenue contribution, presence in regulated Western markets, operating cash flow generation, and demonstrated ability to navigate extreme raw material cost cycles. Companies like Korea Ginseng Corporation with operations across 140+ countries score highly, while firms demonstrating strong cash flow recovery after navigating bezoar price collapses also earn recognition.
Financial data is sourced from FY2025 annual reports filed with stock exchanges (SHA, SZSE, HKEX, TYO, KRX). Production capacity data is verified against corporate filings, factory audit reports, and national pharmaceutical industry association databases. Market size estimates are cross-referenced with Persistence Market Research, Mordor Intelligence, and IQVIA industry reports.
All rankings are updated annually following the publication of audited financial statements. Interim updates may occur in response to major M&A events, significant production capacity expansions, or material changes in regulatory status.
什么造就了领先的中药制造商？
领先的中药制造商通过五大核心竞争优势脱颖而出，这些优势共同在行业巨头和小型生产商之间建立了不可逾越的壁垒。
1. 大规模生产与垂直整合
像广州白云山这样的顶级制造商运营着数十个GMP认证工厂，每年加工数十万吨中药材，从GAP标准种植基地到提取、制剂和分销，实现端到端供应链控制。云南白药的文山工厂是全球最大的三七加工中心，年处理能力超过1万吨。这种垂直深度创造了合同制造商无法复制的成本优势和质量控制能力。
2. 无与伦比的制造自动化投资
领导者与追随者之间的生产力差距正通过自动化投资急剧扩大。津村公司的茨城工厂部署了定制的AGV机器人，在无尘环境中自主处理175公斤的提取容器——单次部署使年产量增加45吨，同时消除了人为错误和交叉污染风险。中国中药在数十个省级地点运营智能提取车间，通过在线近红外光谱对每个生产批次进行实时质量监控。
3. 与创新药企相当的科研投入强度
以岭药业2025年的研发支出达到收入的10.07%（78.8亿元人民币）——这一水平与全球顶级创新药企相当。其专有的“络病理论”已转化为涵盖心血管、呼吸和肿瘤适应症的全面管线，并有III期临床候选药物。韩国人参公社采用系统生物学网络分析，识别出红参中23种活性化合物，靶向9个信号级联中的37个分子通路——将传统医学转变为精准科学。
4. 战略性原材料安全保障
在自然资源价格极端波动的时代，原材料采购策略已成为生死攸关的问题。片仔癀在获得阿根廷天然牛黄进口权（有效期至2027年）方面取得突破，打破了国内数十年的供应垄断。中国中药和津村在20多个药材生产国维持广泛的国际采购网络，而白云山在中国多个省份部署GAP标准种植基地。这种供应链深度将幸存者与在商品价格冲击中倒下的企业区分开来。
5. 多渠道分销与品牌组合管理
顶级制造商维持覆盖超过10万家医疗机构和30万家药店的分销网络（如以岭药业所示），同时通过OTC、保健品和中药化妆品建立消费者品牌。华润三九的收购驱动战略——收购天士力和昆药集团——一夜之间增加了大量处方药制造能力，并转变了其产品组合，推动2025年处方药收入增长101.38%。
1. 大规模生产与垂直整合
像广州白云山这样的顶级制造商运营着数十个GMP认证工厂，每年加工数十万吨中药材，从GAP标准种植基地到提取、制剂和分销，实现端到端供应链控制。云南白药的文山工厂是全球最大的三七加工中心，年处理能力超过1万吨。这种垂直深度创造了合同制造商无法复制的成本优势和质量控制能力。
2. 无与伦比的制造自动化投资
领导者与追随者之间的生产力差距正通过自动化投资急剧扩大。津村公司的茨城工厂部署了定制的AGV机器人，在无尘环境中自主处理175公斤的提取容器——单次部署使年产量增加45吨，同时消除了人为错误和交叉污染风险。中国中药在数十个省级地点运营智能提取车间，通过在线近红外光谱对每个生产批次进行实时质量监控。
3. 与创新药企相当的科研投入强度
以岭药业2025年的研发支出达到收入的10.07%（78.8亿元人民币）——这一水平与全球顶级创新药企相当。其专有的“络病理论”已转化为涵盖心血管、呼吸和肿瘤适应症的全面管线，并有III期临床候选药物。韩国人参公社采用系统生物学网络分析，识别出红参中23种活性化合物，靶向9个信号级联中的37个分子通路——将传统医学转变为精准科学。
4. 战略性原材料安全保障
在自然资源价格极端波动的时代，原材料采购策略已成为生死攸关的问题。片仔癀在获得阿根廷天然牛黄进口权（有效期至2027年）方面取得突破，打破了国内数十年的供应垄断。中国中药和津村在20多个药材生产国维持广泛的国际采购网络，而白云山在中国多个省份部署GAP标准种植基地。这种供应链深度将幸存者与在商品价格冲击中倒下的企业区分开来。
5. 多渠道分销与品牌组合管理
顶级制造商维持覆盖超过10万家医疗机构和30万家药店的分销网络（如以岭药业所示），同时通过OTC、保健品和中药化妆品建立消费者品牌。华润三九的收购驱动战略——收购天士力和昆药集团——一夜之间增加了大量处方药制造能力，并转变了其产品组合，推动2025年处方药收入增长101.38%。
What Makes a Leading TCM Manufacturer?
Leading TCM manufacturers distinguish themselves through five core competitive advantages that together create an unbreachable barrier between industry giants and smaller producers.
1. Massive Production Scale with Vertical Integration
Top manufacturers like Guangzhou Baiyunshan operate dozens of GMP-certified factories processing hundreds of thousands of tons of raw herbs annually, with end-to-end supply chain control from GAP-standard cultivation bases through extraction, formulation, and distribution. Yunnan Baiyao's Wenshan facility is the world's largest Panax notoginseng processing center with 10,000+ ton annual throughput capacity. This vertical depth creates an insurmountable cost advantage and quality control capability that contract manufacturers cannot replicate.
2. Unmatched Investment in Manufacturing Automation
The productivity gap between leaders and followers is widening dramatically through automation investment. Tsumura's Ibaraki factory deploys customized AGV robots that autonomously handle 175 kg extraction containers in dust-free environments — a single deployment increasing annual output by 45 tons while eliminating human error and cross-contamination risks. China TCM operates intelligent extraction workshops across dozens of provincial locations, with online NIR spectroscopy providing real-time quality monitoring of every production batch.
3. Scientific R&D Intensity Matching Innovative Pharma
Yiling Pharmaceutical's 2025 R&D spending reached 10.07% of revenue (CNY 7.88 billion) — a level matching top-tier innovative pharmaceutical companies globally. Its proprietary "collateral disease theory" has been translated into a comprehensive pipeline spanning cardiovascular, respiratory, and oncology indications with Phase III clinical candidates. Korea Ginseng Corporation employs systems biology network analysis to identify 23 active compounds in red ginseng targeting 37 molecular pathways across 9 signaling cascades — transforming traditional medicine into precision science.
4. Strategic Raw Material Security
In an era of extreme natural resource price volatility, raw material sourcing strategy has become existential. Pien Tze Huang's breakthrough in securing Argentine natural bezoar import rights (valid until 2027) broke a decades-long domestic supply monopoly. China TCM and Tsumura maintain extensive international procurement networks across 20+ herb-producing countries, while Baiyunshan deploys GAP-standard cultivation bases across multiple Chinese provinces. This supply chain depth separates survivors from casualties during commodity price shocks.
5. Multi-Channel Distribution and Brand Portfolio Management
Top manufacturers maintain distribution networks spanning 100,000+ medical institutions and 300,000+ pharmacies (as demonstrated by Yiling), while simultaneously building consumer brands across OTC, health supplements, and TCM cosmetics. CR Sanjiu's acquisition-driven strategy — acquiring Tianshili and Kunming Pharma — added massive prescription drug manufacturing capacity overnight and transformed its portfolio mix, driving 101.38% prescription drug revenue growth in 2025.
1. Massive Production Scale with Vertical Integration
Top manufacturers like Guangzhou Baiyunshan operate dozens of GMP-certified factories processing hundreds of thousands of tons of raw herbs annually, with end-to-end supply chain control from GAP-standard cultivation bases through extraction, formulation, and distribution. Yunnan Baiyao's Wenshan facility is the world's largest Panax notoginseng processing center with 10,000+ ton annual throughput capacity. This vertical depth creates an insurmountable cost advantage and quality control capability that contract manufacturers cannot replicate.
2. Unmatched Investment in Manufacturing Automation
The productivity gap between leaders and followers is widening dramatically through automation investment. Tsumura's Ibaraki factory deploys customized AGV robots that autonomously handle 175 kg extraction containers in dust-free environments — a single deployment increasing annual output by 45 tons while eliminating human error and cross-contamination risks. China TCM operates intelligent extraction workshops across dozens of provincial locations, with online NIR spectroscopy providing real-time quality monitoring of every production batch.
3. Scientific R&D Intensity Matching Innovative Pharma
Yiling Pharmaceutical's 2025 R&D spending reached 10.07% of revenue (CNY 7.88 billion) — a level matching top-tier innovative pharmaceutical companies globally. Its proprietary "collateral disease theory" has been translated into a comprehensive pipeline spanning cardiovascular, respiratory, and oncology indications with Phase III clinical candidates. Korea Ginseng Corporation employs systems biology network analysis to identify 23 active compounds in red ginseng targeting 37 molecular pathways across 9 signaling cascades — transforming traditional medicine into precision science.
4. Strategic Raw Material Security
In an era of extreme natural resource price volatility, raw material sourcing strategy has become existential. Pien Tze Huang's breakthrough in securing Argentine natural bezoar import rights (valid until 2027) broke a decades-long domestic supply monopoly. China TCM and Tsumura maintain extensive international procurement networks across 20+ herb-producing countries, while Baiyunshan deploys GAP-standard cultivation bases across multiple Chinese provinces. This supply chain depth separates survivors from casualties during commodity price shocks.
5. Multi-Channel Distribution and Brand Portfolio Management
Top manufacturers maintain distribution networks spanning 100,000+ medical institutions and 300,000+ pharmacies (as demonstrated by Yiling), while simultaneously building consumer brands across OTC, health supplements, and TCM cosmetics. CR Sanjiu's acquisition-driven strategy — acquiring Tianshili and Kunming Pharma — added massive prescription drug manufacturing capacity overnight and transformed its portfolio mix, driving 101.38% prescription drug revenue growth in 2025.
2025-2026年中药制造如何变化？
中药制造业正经历其数千年历史上最具颠覆性的转型，由五个相互关联的力量驱动，重塑着生产经济学、质量标准与竞争格局。
1. 集中带量采购（VBP）重塑盈利模式
中国针对中药配方颗粒和专利药的全国性VBP计划从根本上改变了制造业格局。中标产品价格下降30-70%，依赖单一产品或纯医院渠道销售的制造商遭受了毁灭性的利润压缩。中国中药在2025年录得史上首次45.8亿元人民币净亏损，原因是VBP实施恰逢原材料库存减值和49.5亿元人民币商誉减值。相比之下，拥有多元化OTC和消费者健康产品组合的垂直整合制造商——如云南白药及其主导的牙膏业务——展现了显著的利润韧性。
2. 原材料稀缺与极端价格波动
2024-2025年的天然牛黄周期为行业提供了一次严峻的压力测试。价格从约每公斤50万元人民币飙升至每公斤180万元人民币，随后在2025年暴跌至每公斤52万元人民币。这给制造商造成了致命的时机错配——像片仔癀这样的公司用2025年的生产消化了2024年高价库存，导致其自2003年IPO以来首次出现收入（-16.56%）和净利润（-27.49%）同时下降，核心产品库存激增265.53%。有远见的制造商现在正积极寻求国际资源多元化、内部种植和合成生物学替代方案，以打破自然资源垄断。
3. 制造自动化拉大竞争差距
一级和二级制造商之间的技术差距正变得不可逾越。行业领导者正在部署工业4.0系统——AGV车队、数字孪生模拟、物联网连接的提取集群和AI驱动的质量预测——而较小的制造商仍依赖劳动力。津村在其茨城工厂部署AGV以及白云山被选为省级“先进数字工厂”就是这一趋势的例证。这些投资的资本密集度形成了有利于大型、资金充裕参与者的自然整合力量。
4. 中药与现代生物制药平台的融合
传统中药制造与现代生物制药之间的界限正在消融。以岭药业的双平台战略——呼吸系统中药主导地位加上18个美国ANDA批准的仿制药和一个三期肿瘤候选药物（XY0206）——代表了新的行业模板。制造商越来越多地在同一企业架构下建设化学合成、生物制剂和中药提取能力，利用共享的质量体系、监管专业知识和分销网络。
5. 国际监管接受与市场准入
中药制造商正在获得前所未有的受监管西方市场准入。同仁堂在2026年初获得了加拿大市场产品许可证；以岭的ANDA产品组合提供了美国市场准入；津村的汉方提取物在日本国民健康保险体系内被处方使用。通过系统生物学和网络药理学对中药机制的科学验证——正如韩国人参公社发表的研究显示红参的23种活性化合物靶向37条分子通路——正在加速监管接受。全球中药市场预计到2031年将达到5130亿美元，其中北美是增长最快的区域细分市场。
1. 集中带量采购（VBP）重塑盈利模式
中国针对中药配方颗粒和专利药的全国性VBP计划从根本上改变了制造业格局。中标产品价格下降30-70%，依赖单一产品或纯医院渠道销售的制造商遭受了毁灭性的利润压缩。中国中药在2025年录得史上首次45.8亿元人民币净亏损，原因是VBP实施恰逢原材料库存减值和49.5亿元人民币商誉减值。相比之下，拥有多元化OTC和消费者健康产品组合的垂直整合制造商——如云南白药及其主导的牙膏业务——展现了显著的利润韧性。
2. 原材料稀缺与极端价格波动
2024-2025年的天然牛黄周期为行业提供了一次严峻的压力测试。价格从约每公斤50万元人民币飙升至每公斤180万元人民币，随后在2025年暴跌至每公斤52万元人民币。这给制造商造成了致命的时机错配——像片仔癀这样的公司用2025年的生产消化了2024年高价库存，导致其自2003年IPO以来首次出现收入（-16.56%）和净利润（-27.49%）同时下降，核心产品库存激增265.53%。有远见的制造商现在正积极寻求国际资源多元化、内部种植和合成生物学替代方案，以打破自然资源垄断。
3. 制造自动化拉大竞争差距
一级和二级制造商之间的技术差距正变得不可逾越。行业领导者正在部署工业4.0系统——AGV车队、数字孪生模拟、物联网连接的提取集群和AI驱动的质量预测——而较小的制造商仍依赖劳动力。津村在其茨城工厂部署AGV以及白云山被选为省级“先进数字工厂”就是这一趋势的例证。这些投资的资本密集度形成了有利于大型、资金充裕参与者的自然整合力量。
4. 中药与现代生物制药平台的融合
传统中药制造与现代生物制药之间的界限正在消融。以岭药业的双平台战略——呼吸系统中药主导地位加上18个美国ANDA批准的仿制药和一个三期肿瘤候选药物（XY0206）——代表了新的行业模板。制造商越来越多地在同一企业架构下建设化学合成、生物制剂和中药提取能力，利用共享的质量体系、监管专业知识和分销网络。
5. 国际监管接受与市场准入
中药制造商正在获得前所未有的受监管西方市场准入。同仁堂在2026年初获得了加拿大市场产品许可证；以岭的ANDA产品组合提供了美国市场准入；津村的汉方提取物在日本国民健康保险体系内被处方使用。通过系统生物学和网络药理学对中药机制的科学验证——正如韩国人参公社发表的研究显示红参的23种活性化合物靶向37条分子通路——正在加速监管接受。全球中药市场预计到2031年将达到5130亿美元，其中北美是增长最快的区域细分市场。
How Is Traditional Chinese Medicine Manufacturing Changing in 2025-2026?
The TCM manufacturing industry is experiencing the most disruptive transformation in its multi-millennia history, driven by five interconnected forces reshaping production economics, quality standards, and competitive dynamics.
1. Centralized Volume-Based Procurement (VBP) Restructuring Profit Models
China's nationwide VBP program for TCM formula granules and patent medicines has fundamentally altered the manufacturing landscape. With price reductions of 30-70% on tendered products, manufacturers dependent on single-product or pure hospital-channel sales have suffered devastating margin compression. China TCM recorded its first-ever CNY 4.58 billion net loss in 2025 as VBP implementation coincided with raw material inventory write-downs and CNY 4.95 billion in goodwill impairments. In contrast, vertically integrated manufacturers with diversified OTC and consumer health portfolios — such as Yunnan Baiyao with its dominant toothpaste business — have demonstrated remarkable margin resilience.
2. Raw Material Scarcity and Extreme Price Volatility
The 2024-2025 natural bezoar cycle provided a brutal stress test for the industry. Prices surged from approximately CNY 500,000/kg to CNY 1.8 million/kg before collapsing to CNY 520,000/kg in 2025. This created a fatal timing mismatch for manufacturers — companies like Pien Tze Huang settled 2024's peak-price inventory through 2025 production, causing its first simultaneous revenue (-16.56%) and net profit (-27.49%) decline since its 2003 IPO, with core product inventory exploding 265.53%. Forward-thinking manufacturers are now aggressively pursuing international resource diversification, in-house cultivation, and synthetic biology alternatives to break natural resource monopolies.
3. Manufacturing Automation Widening the Competitive Gap
The technology gap between tier-1 and tier-2 manufacturers is becoming unbridgeable. Industry leaders are deploying Industry 4.0 systems — AGV fleets, digital twin simulations, IoT-connected extraction clusters, and AI-powered quality prediction — while smaller manufacturers remain labor-dependent. Tsumura's AGV deployment at Ibaraki and Baiyunshan's selection as a provincial "Advanced Digital Factory" exemplify this trend. The capital intensity of these investments creates a natural consolidation force favoring large, well-financed players.
4. Integration of TCM with Modern Biopharmaceutical Platforms
The boundary between traditional TCM manufacturing and modern biopharma is dissolving. Yiling Pharmaceutical's dual-platform strategy — respiratory TCM dominance combined with 18 US ANDA-approved generic drugs and a Phase III oncology candidate (XY0206) — represents the new industry template. Manufacturers are increasingly building capabilities across chemical synthesis, biologics, and TCM extraction under one corporate roof, leveraging shared quality systems, regulatory expertise, and distribution networks.
5. International Regulatory Acceptance and Market Access
TCM manufacturers are achieving unprecedented access to regulated Western markets. Tongrentang secured Canadian market product licenses in early 2026; Yiling's ANDA portfolio provides US market entry; and Tsumura's Kampo extracts are prescribed within Japan's national health insurance system. The scientific validation of TCM mechanisms through systems biology and network pharmacology — as demonstrated by KGC's published research on red ginseng's 23 active compounds targeting 37 molecular pathways — is accelerating regulatory acceptance. The global TCM market is projected to reach USD 513 billion by 2031, with North America being the fastest-growing regional segment.
1. Centralized Volume-Based Procurement (VBP) Restructuring Profit Models
China's nationwide VBP program for TCM formula granules and patent medicines has fundamentally altered the manufacturing landscape. With price reductions of 30-70% on tendered products, manufacturers dependent on single-product or pure hospital-channel sales have suffered devastating margin compression. China TCM recorded its first-ever CNY 4.58 billion net loss in 2025 as VBP implementation coincided with raw material inventory write-downs and CNY 4.95 billion in goodwill impairments. In contrast, vertically integrated manufacturers with diversified OTC and consumer health portfolios — such as Yunnan Baiyao with its dominant toothpaste business — have demonstrated remarkable margin resilience.
2. Raw Material Scarcity and Extreme Price Volatility
The 2024-2025 natural bezoar cycle provided a brutal stress test for the industry. Prices surged from approximately CNY 500,000/kg to CNY 1.8 million/kg before collapsing to CNY 520,000/kg in 2025. This created a fatal timing mismatch for manufacturers — companies like Pien Tze Huang settled 2024's peak-price inventory through 2025 production, causing its first simultaneous revenue (-16.56%) and net profit (-27.49%) decline since its 2003 IPO, with core product inventory exploding 265.53%. Forward-thinking manufacturers are now aggressively pursuing international resource diversification, in-house cultivation, and synthetic biology alternatives to break natural resource monopolies.
3. Manufacturing Automation Widening the Competitive Gap
The technology gap between tier-1 and tier-2 manufacturers is becoming unbridgeable. Industry leaders are deploying Industry 4.0 systems — AGV fleets, digital twin simulations, IoT-connected extraction clusters, and AI-powered quality prediction — while smaller manufacturers remain labor-dependent. Tsumura's AGV deployment at Ibaraki and Baiyunshan's selection as a provincial "Advanced Digital Factory" exemplify this trend. The capital intensity of these investments creates a natural consolidation force favoring large, well-financed players.
4. Integration of TCM with Modern Biopharmaceutical Platforms
The boundary between traditional TCM manufacturing and modern biopharma is dissolving. Yiling Pharmaceutical's dual-platform strategy — respiratory TCM dominance combined with 18 US ANDA-approved generic drugs and a Phase III oncology candidate (XY0206) — represents the new industry template. Manufacturers are increasingly building capabilities across chemical synthesis, biologics, and TCM extraction under one corporate roof, leveraging shared quality systems, regulatory expertise, and distribution networks.
5. International Regulatory Acceptance and Market Access
TCM manufacturers are achieving unprecedented access to regulated Western markets. Tongrentang secured Canadian market product licenses in early 2026; Yiling's ANDA portfolio provides US market entry; and Tsumura's Kampo extracts are prescribed within Japan's national health insurance system. The scientific validation of TCM mechanisms through systems biology and network pharmacology — as demonstrated by KGC's published research on red ginseng's 23 active compounds targeting 37 molecular pathways — is accelerating regulatory acceptance. The global TCM market is projected to reach USD 513 billion by 2031, with North America being the fastest-growing regional segment.
采购团队在评估中药制造商时应关注什么？
评估中药和保健品制造合作伙伴的采购专业人士必须超越价格清单，评估五个关键能力维度，这些维度决定了长期供应可靠性、质量一致性和法规合规性。
1. 生产能力验证与可扩展性
要求提供年度生药材处理量（公吨）、提取能力（升/批次）和成品制剂产量（单位/年）的书面证据。领先制造商应展示多工厂冗余——广州白云山通过数十家子公司工厂运营，确保供应链中无单点故障。直接与发证监管机构（中国NMPA、日本PMDA、韩国MFDS）验证GMP证书的真实性。评估制造商是否能在12个月内将产量扩大30-50%，以适应需求激增。
2. 质量管理体系成熟度
评估制造商的质量基础设施，超越基本的GMP合规性。寻找在线过程分析技术的部署，如用于实时批次监控的近红外光谱、用于多组分鉴定的高效液相色谱指纹图谱，以及在来料、在制品和成品阶段的重金属/农药残留检测。津村基于AGV的无尘处理和韩国人参公社的多阶段质量门代表了最佳实践。要求提供制造商的批次拒收率和偏差调查记录，作为质量文化成熟度的指标。
3. 原材料供应链韧性
鉴于天然产品原材料的极端波动性，从三个维度评估制造商的供应链策略：(a) 自营种植——制造商是否拥有GAP标准药材种植基地，关键原材料的自供比例是多少？(b) 地理多元化——制造商从多少个国家采购，单一产地关键材料的集中风险如何？(c) 库存缓冲策略——制造商对价格波动大的材料采取什么样的战略库存政策？具有国际进口多元化的公司（例如片仔癀的阿根廷牛黄许可证）展示了卓越的供应链策略。
4. 监管记录与国际认证
验证制造商在目标市场的监管状况。对于美国市场准入，确认FDA企业注册和药品列名状态。对于欧盟市场，验证EU GMP认证和传统草药药品注册。对于具有特定中药法规的市场（澳大利亚TGA、加拿大NHP、新加坡HSA），确认具体的产品注册。通过FDA公共数据库检查制造商的FDA警告信和进口警报历史。5年以上的清洁监管记录是一级制造商的最低期望。
5. 创新管线与技术路线图
评估制造商对未来能力的投资：(a) 研发支出占收入的比例——以岭药业10.07%的研发强度树立了行业标杆，(b) 正在开发的新型药物递送系统（缓释颗粒、透皮贴剂、脂质体制剂），(c) 数字化制造举措（MES部署、数字孪生实施、人工智能驱动的工艺优化），(d) 已发表的同行评审临床研究，证明产品疗效。大力投资现代化的制造商更有可能在多年供应关系中保持质量领先和法规合规。
1. 生产能力验证与可扩展性
要求提供年度生药材处理量（公吨）、提取能力（升/批次）和成品制剂产量（单位/年）的书面证据。领先制造商应展示多工厂冗余——广州白云山通过数十家子公司工厂运营，确保供应链中无单点故障。直接与发证监管机构（中国NMPA、日本PMDA、韩国MFDS）验证GMP证书的真实性。评估制造商是否能在12个月内将产量扩大30-50%，以适应需求激增。
2. 质量管理体系成熟度
评估制造商的质量基础设施，超越基本的GMP合规性。寻找在线过程分析技术的部署，如用于实时批次监控的近红外光谱、用于多组分鉴定的高效液相色谱指纹图谱，以及在来料、在制品和成品阶段的重金属/农药残留检测。津村基于AGV的无尘处理和韩国人参公社的多阶段质量门代表了最佳实践。要求提供制造商的批次拒收率和偏差调查记录，作为质量文化成熟度的指标。
3. 原材料供应链韧性
鉴于天然产品原材料的极端波动性，从三个维度评估制造商的供应链策略：(a) 自营种植——制造商是否拥有GAP标准药材种植基地，关键原材料的自供比例是多少？(b) 地理多元化——制造商从多少个国家采购，单一产地关键材料的集中风险如何？(c) 库存缓冲策略——制造商对价格波动大的材料采取什么样的战略库存政策？具有国际进口多元化的公司（例如片仔癀的阿根廷牛黄许可证）展示了卓越的供应链策略。
4. 监管记录与国际认证
验证制造商在目标市场的监管状况。对于美国市场准入，确认FDA企业注册和药品列名状态。对于欧盟市场，验证EU GMP认证和传统草药药品注册。对于具有特定中药法规的市场（澳大利亚TGA、加拿大NHP、新加坡HSA），确认具体的产品注册。通过FDA公共数据库检查制造商的FDA警告信和进口警报历史。5年以上的清洁监管记录是一级制造商的最低期望。
5. 创新管线与技术路线图
评估制造商对未来能力的投资：(a) 研发支出占收入的比例——以岭药业10.07%的研发强度树立了行业标杆，(b) 正在开发的新型药物递送系统（缓释颗粒、透皮贴剂、脂质体制剂），(c) 数字化制造举措（MES部署、数字孪生实施、人工智能驱动的工艺优化），(d) 已发表的同行评审临床研究，证明产品疗效。大力投资现代化的制造商更有可能在多年供应关系中保持质量领先和法规合规。
What Should Procurement Teams Look for When Evaluating TCM Manufacturers?
Procurement professionals evaluating TCM and health product manufacturing partners must look beyond price lists to assess five critical capability dimensions that determine long-term supply reliability, quality consistency, and regulatory compliance.
1. Production Capacity Verification and Scalability
Request documented evidence of annual raw herb processing throughput (metric tons), extraction capacity (liters/batch), and finished formulation output (units/year). Leading manufacturers should demonstrate multi-plant redundancy — Guangzhou Baiyunshan operates through dozens of subsidiary factories, ensuring no single-point-of-failure in the supply chain. Verify GMP certificate authenticity directly with issuing regulatory authorities (NMPA in China, PMDA in Japan, MFDS in Korea). Assess whether the manufacturer can scale output by 30-50% within 12 months to accommodate demand surges.
2. Quality Management System Maturity
Evaluate the manufacturer's quality infrastructure beyond basic GMP compliance. Look for deployment of online process analytical technology (PAT) such as NIR spectroscopy for real-time batch monitoring, HPLC fingerprinting for multi-component authentication, and heavy metal/pesticide residue testing at incoming raw material, in-process, and finished product stages. Tsumura's AGV-based dust-free handling and KGC's multi-stage quality gates represent best-in-class approaches. Request the manufacturer's batch rejection rate and deviation investigation records as indicators of quality culture maturity.
3. Raw Material Supply Chain Resilience
Given the extreme volatility in natural product raw materials, assess the manufacturer's supply chain strategy across three dimensions: (a) captive cultivation — does the manufacturer own GAP-standard herb cultivation bases, and what percentage of critical raw materials are self-supplied?, (b) geographic diversification — how many countries does the manufacturer source from, and what is the concentration risk for single-origin critical materials?, (c) inventory buffer strategy — what is the manufacturer's policy for strategic inventory of price-volatile materials? Companies with international import diversification (e.g., Pien Tze Huang's Argentine bezoar license) demonstrate superior supply chain strategy.
4. Regulatory Track Record and International Certifications
Verify the manufacturer's regulatory standing across target markets. For US market entry, confirm FDA establishment registration and drug listing status. For EU markets, verify EU GMP certification and Traditional Herbal Medicinal Product registration. For markets with specific TCM regulations (Australia TGA, Canada NHP, Singapore HSA), confirm specific product registrations. Check the manufacturer's FDA warning letter and import alert history through the FDA's public database. A clean regulatory record across 5+ years is the minimum expectation for tier-1 manufacturers.
5. Innovation Pipeline and Technology Roadmap
Assess the manufacturer's investment in future capabilities: (a) R&D spending as a percentage of revenue — Yiling's 10.07% R&D intensity sets the industry benchmark, (b) novel drug delivery systems under development (sustained-release granules, transdermal patches, liposomal formulations), (c) digital manufacturing initiatives (MES deployment, digital twin implementation, AI-driven process optimization), (d) published peer-reviewed clinical research demonstrating product efficacy. Manufacturers investing heavily in modernization are more likely to maintain quality leadership and regulatory compliance over multi-year supply relationships.
1. Production Capacity Verification and Scalability
Request documented evidence of annual raw herb processing throughput (metric tons), extraction capacity (liters/batch), and finished formulation output (units/year). Leading manufacturers should demonstrate multi-plant redundancy — Guangzhou Baiyunshan operates through dozens of subsidiary factories, ensuring no single-point-of-failure in the supply chain. Verify GMP certificate authenticity directly with issuing regulatory authorities (NMPA in China, PMDA in Japan, MFDS in Korea). Assess whether the manufacturer can scale output by 30-50% within 12 months to accommodate demand surges.
2. Quality Management System Maturity
Evaluate the manufacturer's quality infrastructure beyond basic GMP compliance. Look for deployment of online process analytical technology (PAT) such as NIR spectroscopy for real-time batch monitoring, HPLC fingerprinting for multi-component authentication, and heavy metal/pesticide residue testing at incoming raw material, in-process, and finished product stages. Tsumura's AGV-based dust-free handling and KGC's multi-stage quality gates represent best-in-class approaches. Request the manufacturer's batch rejection rate and deviation investigation records as indicators of quality culture maturity.
3. Raw Material Supply Chain Resilience
Given the extreme volatility in natural product raw materials, assess the manufacturer's supply chain strategy across three dimensions: (a) captive cultivation — does the manufacturer own GAP-standard herb cultivation bases, and what percentage of critical raw materials are self-supplied?, (b) geographic diversification — how many countries does the manufacturer source from, and what is the concentration risk for single-origin critical materials?, (c) inventory buffer strategy — what is the manufacturer's policy for strategic inventory of price-volatile materials? Companies with international import diversification (e.g., Pien Tze Huang's Argentine bezoar license) demonstrate superior supply chain strategy.
4. Regulatory Track Record and International Certifications
Verify the manufacturer's regulatory standing across target markets. For US market entry, confirm FDA establishment registration and drug listing status. For EU markets, verify EU GMP certification and Traditional Herbal Medicinal Product registration. For markets with specific TCM regulations (Australia TGA, Canada NHP, Singapore HSA), confirm specific product registrations. Check the manufacturer's FDA warning letter and import alert history through the FDA's public database. A clean regulatory record across 5+ years is the minimum expectation for tier-1 manufacturers.
5. Innovation Pipeline and Technology Roadmap
Assess the manufacturer's investment in future capabilities: (a) R&D spending as a percentage of revenue — Yiling's 10.07% R&D intensity sets the industry benchmark, (b) novel drug delivery systems under development (sustained-release granules, transdermal patches, liposomal formulations), (c) digital manufacturing initiatives (MES deployment, digital twin implementation, AI-driven process optimization), (d) published peer-reviewed clinical research demonstrating product efficacy. Manufacturers investing heavily in modernization are more likely to maintain quality leadership and regulatory compliance over multi-year supply relationships.
哪些中药制造商在可持续发展和供应链道德方面领先？
中药制造中的可持续发展领导力涵盖三个相互关联的领域：自然资源的环保管理、道德供应链管理以及制造运营中的社会责任。
1. 生物多样性保护与可持续采购
中药行业对野生采集自然资源的根本依赖造成了生存性的可持续性挑战。领先的制造商正在开创将生产与野生资源枯竭脱钩的方法。云南白药在文山运营着世界上最大的栽培三七基地，拥有数千公顷GAP认证的种植面积，基本上消除了对这种关键成分的野生采集。津村在其中国供应基地建立了50多种药用植物的可持续种植规程，直接与农业合作社合作，确保生态可持续性和种植者的经济可行性。韩国人参公社的合同种植系统用于韩国红参，维持6年种植周期并强制轮作，在保护土壤健康的同时确保优质原料。
2. 制造环境足迹减少
中药提取和制剂是能源密集型的，草药清洗、煎煮和浓缩过程需要大量水。领先的制造商正在投资环保技术：白云山的先进数字工厂采用闭环水循环系统，在提取操作中将淡水消耗减少40-60%。太极集团的涪陵工厂实施了溶剂回收系统，捕获并再利用提取过程中的乙醇，减少挥发性有机化合物（VOC）排放。以岭药业在石家庄和衡水的智能制造基地配备了能源管理系统，优化生产调度中的公用事业消耗，与传统中药厂相比实现了15-20%的能源强度降低。
3. 道德劳工实践与社区发展
中药供应链涉及中国农村和东南亚的数百万小农户和采集者。华润三九作为国药集团的子公司，遵守国有企业社会责任标准，包括对合同草药种植者的公平定价承诺，以及在采购地区投资农村医疗基础设施。云南白药的文山业务为中国欠发达地区之一提供了数千个稳定就业岗位，并提供全面的社会保险覆盖和技能发展计划。同仁堂的400年传承包括与特定草药生产社区的持久关系，创造了代际经济稳定。
4. ESG报告与透明度
在前10名中，在主要交易所（上交所、深交所、港交所、东京交易所）上市的制造商面临日益严格的ESG披露要求。中国中药尽管在2025年面临财务困难，但仍保持了全面的环境报告，涵盖其全国工厂网络的水资源使用、能源消耗和废物管理。津村发布详细的综合报告，涵盖其全球供应链可持续性举措，包括可持续草药采购百分比和碳足迹减少目标的具体指标。整个行业趋势是提高透明度，尽管该行业在标准化ESG指标报告方面仍落后于西方制药同行。
5. 循环经济与废物价值化
中药可持续性的一个新兴前沿是提取残留物的价值化。传统提取过程通常只利用20-40%的输入生物质，其余作为废物处理。创新型制造商正在探索废弃草药材料的应用：白云山和其他大型加工商正在试点项目，将提取残留物转化为其种植基地的有机肥料，创建闭环营养循环。与学术机构的研究合作正在探索从加工废物中提取次生代谢物的潜力，可能开辟额外的收入来源，同时减少环境负担。这代表了中药制造领域可持续性差异化的一个重要且尚未充分开发的机遇。
1. 生物多样性保护与可持续采购
中药行业对野生采集自然资源的根本依赖造成了生存性的可持续性挑战。领先的制造商正在开创将生产与野生资源枯竭脱钩的方法。云南白药在文山运营着世界上最大的栽培三七基地，拥有数千公顷GAP认证的种植面积，基本上消除了对这种关键成分的野生采集。津村在其中国供应基地建立了50多种药用植物的可持续种植规程，直接与农业合作社合作，确保生态可持续性和种植者的经济可行性。韩国人参公社的合同种植系统用于韩国红参，维持6年种植周期并强制轮作，在保护土壤健康的同时确保优质原料。
2. 制造环境足迹减少
中药提取和制剂是能源密集型的，草药清洗、煎煮和浓缩过程需要大量水。领先的制造商正在投资环保技术：白云山的先进数字工厂采用闭环水循环系统，在提取操作中将淡水消耗减少40-60%。太极集团的涪陵工厂实施了溶剂回收系统，捕获并再利用提取过程中的乙醇，减少挥发性有机化合物（VOC）排放。以岭药业在石家庄和衡水的智能制造基地配备了能源管理系统，优化生产调度中的公用事业消耗，与传统中药厂相比实现了15-20%的能源强度降低。
3. 道德劳工实践与社区发展
中药供应链涉及中国农村和东南亚的数百万小农户和采集者。华润三九作为国药集团的子公司，遵守国有企业社会责任标准，包括对合同草药种植者的公平定价承诺，以及在采购地区投资农村医疗基础设施。云南白药的文山业务为中国欠发达地区之一提供了数千个稳定就业岗位，并提供全面的社会保险覆盖和技能发展计划。同仁堂的400年传承包括与特定草药生产社区的持久关系，创造了代际经济稳定。
4. ESG报告与透明度
在前10名中，在主要交易所（上交所、深交所、港交所、东京交易所）上市的制造商面临日益严格的ESG披露要求。中国中药尽管在2025年面临财务困难，但仍保持了全面的环境报告，涵盖其全国工厂网络的水资源使用、能源消耗和废物管理。津村发布详细的综合报告，涵盖其全球供应链可持续性举措，包括可持续草药采购百分比和碳足迹减少目标的具体指标。整个行业趋势是提高透明度，尽管该行业在标准化ESG指标报告方面仍落后于西方制药同行。
5. 循环经济与废物价值化
中药可持续性的一个新兴前沿是提取残留物的价值化。传统提取过程通常只利用20-40%的输入生物质，其余作为废物处理。创新型制造商正在探索废弃草药材料的应用：白云山和其他大型加工商正在试点项目，将提取残留物转化为其种植基地的有机肥料，创建闭环营养循环。与学术机构的研究合作正在探索从加工废物中提取次生代谢物的潜力，可能开辟额外的收入来源，同时减少环境负担。这代表了中药制造领域可持续性差异化的一个重要且尚未充分开发的机遇。
Which TCM Manufacturers Lead in Sustainability and Supply Chain Ethics?
Sustainability leadership in TCM manufacturing encompasses three interconnected domains: environmental stewardship of natural resources, ethical supply chain management, and social responsibility in manufacturing operations.
1. Biodiversity Conservation and Sustainable Sourcing
The TCM industry's fundamental dependence on wild-harvested natural resources creates an existential sustainability challenge. Leading manufacturers are pioneering approaches to decouple production from wild-harvested resource depletion. Yunnan Baiyao operates the world's largest cultivated Panax notoginseng base in Wenshan, with thousands of hectares under GAP-certified cultivation that has essentially eliminated wild harvesting for this critical ingredient. Tsumura has established sustainable cultivation protocols for over 50 medicinal plant species across its Chinese supply base, working directly with farming cooperatives to ensure both ecological sustainability and economic viability for growers. Korea Ginseng Corporation's contract farming system for Korean red ginseng maintains 6-year cultivation cycles with mandatory field rotation, preserving soil health while ensuring premium quality raw materials.
2. Manufacturing Environmental Footprint Reduction
TCM extraction and formulation is energy-intensive, with large-scale water consumption for herb washing, decoction, and concentration processes. Leading manufacturers are investing in environmental technologies: Baiyunshan's advanced digital factories employ closed-loop water recycling systems that reduce freshwater consumption by 40-60% in extraction operations. Taiji Group's Fuling facilities have implemented solvent recovery systems capturing and reusing ethanol from extraction processes, reducing volatile organic compound (VOC) emissions. Yiling Pharmaceutical's smart manufacturing bases in Shijiazhuang and Hengshui feature energy management systems that optimize utility consumption across production scheduling, achieving 15-20% energy intensity reduction compared to conventional TCM plants.
3. Ethical Labor Practices and Community Development
The TCM supply chain involves millions of smallholder farmers and collectors across rural China and Southeast Asia. CR Sanjiu, as a Sinopharm subsidiary, adheres to state-owned enterprise social responsibility standards including fair pricing commitments for contracted herb growers and investment in rural healthcare infrastructure in sourcing regions. Yunnan Baiyao's Wenshan operations provide stable employment for thousands in one of China's less developed regions, with comprehensive social insurance coverage and skills development programs. Tongrentang's 400-year heritage includes enduring relationships with specific herb-producing communities, creating intergenerational economic stability.
4. ESG Reporting and Transparency
Among the top 10, listed manufacturers on major exchanges (SHA, SZSE, HKEX, TYO) are subject to increasing ESG disclosure requirements. China TCM, despite its 2025 financial difficulties, maintained comprehensive environmental reporting covering water usage, energy consumption, and waste management across its national factory network. Tsumura publishes detailed integrated reports covering its global supply chain sustainability initiatives, including specific metrics on sustainable herb sourcing percentages and carbon footprint reduction targets. Industry-wide, the trend is toward greater transparency, though the sector still lags behind Western pharmaceutical peers in standardized ESG metric reporting.
5. Circular Economy and Waste Valorization
An emerging frontier in TCM sustainability is the valorization of extraction residues. Traditional extraction processes typically utilize only 20-40% of input biomass, with the remainder disposed as waste. Innovative manufacturers are exploring applications for spent herb materials: Baiyunshan and other large processors are piloting programs to convert extraction residues into organic fertilizers for their cultivation bases, creating closed-loop nutrient cycles. Research collaborations with academic institutions are exploring the potential for secondary metabolite extraction from processing waste, potentially unlocking additional revenue streams while reducing environmental burden. This represents a significant under-exploited opportunity for sustainability differentiation in the TCM manufacturing sector.
1. Biodiversity Conservation and Sustainable Sourcing
The TCM industry's fundamental dependence on wild-harvested natural resources creates an existential sustainability challenge. Leading manufacturers are pioneering approaches to decouple production from wild-harvested resource depletion. Yunnan Baiyao operates the world's largest cultivated Panax notoginseng base in Wenshan, with thousands of hectares under GAP-certified cultivation that has essentially eliminated wild harvesting for this critical ingredient. Tsumura has established sustainable cultivation protocols for over 50 medicinal plant species across its Chinese supply base, working directly with farming cooperatives to ensure both ecological sustainability and economic viability for growers. Korea Ginseng Corporation's contract farming system for Korean red ginseng maintains 6-year cultivation cycles with mandatory field rotation, preserving soil health while ensuring premium quality raw materials.
2. Manufacturing Environmental Footprint Reduction
TCM extraction and formulation is energy-intensive, with large-scale water consumption for herb washing, decoction, and concentration processes. Leading manufacturers are investing in environmental technologies: Baiyunshan's advanced digital factories employ closed-loop water recycling systems that reduce freshwater consumption by 40-60% in extraction operations. Taiji Group's Fuling facilities have implemented solvent recovery systems capturing and reusing ethanol from extraction processes, reducing volatile organic compound (VOC) emissions. Yiling Pharmaceutical's smart manufacturing bases in Shijiazhuang and Hengshui feature energy management systems that optimize utility consumption across production scheduling, achieving 15-20% energy intensity reduction compared to conventional TCM plants.
3. Ethical Labor Practices and Community Development
The TCM supply chain involves millions of smallholder farmers and collectors across rural China and Southeast Asia. CR Sanjiu, as a Sinopharm subsidiary, adheres to state-owned enterprise social responsibility standards including fair pricing commitments for contracted herb growers and investment in rural healthcare infrastructure in sourcing regions. Yunnan Baiyao's Wenshan operations provide stable employment for thousands in one of China's less developed regions, with comprehensive social insurance coverage and skills development programs. Tongrentang's 400-year heritage includes enduring relationships with specific herb-producing communities, creating intergenerational economic stability.
4. ESG Reporting and Transparency
Among the top 10, listed manufacturers on major exchanges (SHA, SZSE, HKEX, TYO) are subject to increasing ESG disclosure requirements. China TCM, despite its 2025 financial difficulties, maintained comprehensive environmental reporting covering water usage, energy consumption, and waste management across its national factory network. Tsumura publishes detailed integrated reports covering its global supply chain sustainability initiatives, including specific metrics on sustainable herb sourcing percentages and carbon footprint reduction targets. Industry-wide, the trend is toward greater transparency, though the sector still lags behind Western pharmaceutical peers in standardized ESG metric reporting.
5. Circular Economy and Waste Valorization
An emerging frontier in TCM sustainability is the valorization of extraction residues. Traditional extraction processes typically utilize only 20-40% of input biomass, with the remainder disposed as waste. Innovative manufacturers are exploring applications for spent herb materials: Baiyunshan and other large processors are piloting programs to convert extraction residues into organic fertilizers for their cultivation bases, creating closed-loop nutrient cycles. Research collaborations with academic institutions are exploring the potential for secondary metabolite extraction from processing waste, potentially unlocking additional revenue streams while reducing environmental burden. This represents a significant under-exploited opportunity for sustainability differentiation in the TCM manufacturing sector.